Form 4: Neogenomics Executive Alicia C. Olivo Reports Stock Option and Unit Grants
SEC Form 4 Filing
Alicia C. Olivo, General Counsel of Neogenomics, reports the acquisition of stock options and restricted/performance stock units.
Summary
- This Form 4 filing details changes in beneficial ownership of Neogenomics Inc. securities by Alicia C. Olivo, the General Counsel.
- On February 23, 2024, Ms. Olivo was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units.
- The stock options vest ratably over three years.
- The restricted stock units also vest ratably over three years.
- The performance stock units vest based on share and revenue growth goals, with a maximum of 37,996 shares potentially vesting.
- Ms. Olivo also directly owns 34,866 shares of common stock.
- She holds various stock options granted between 2019 and 2023, with exercise prices ranging from $9.45 to $48.99.
- She also holds restricted and performance stock units granted in 2023.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, indicating standard executive compensation practices. It's neutral in sentiment, reflecting typical corporate governance.
Positives
- The grant of stock options and restricted/performance stock units aligns Ms. Olivo's interests with those of shareholders.
- The vesting of performance stock units is tied to company performance metrics, incentivizing growth.
Future Outlook
The vesting of performance stock units is contingent on the achievement of certain share and revenue growth goals.
Industry Context
Stock option and RSU grants are common practice to incentivize executives in publicly traded companies, particularly in the biotech and healthcare sectors.
Comparison to Industry Standards
- Equity compensation practices vary across the diagnostics and biotech industries.
- Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and RSUs as part of their executive compensation packages.
- The size and vesting schedules of these grants are typically benchmarked against peer companies to ensure competitiveness.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 02/23/2027 | Vesting start date for performance stock units granted on February 23, 2024. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
| 02/27/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.